Guggenheim upgraded shares of Avalyn Pharma (NASDAQ:AVLN – Free Report) to a strong-buy rating in a research note released on Monday morning,Zacks.com reports.
Other research analysts have also recently issued research reports about the company. Jefferies Financial Group initiated coverage on Avalyn Pharma in a research note on Monday. They issued a “buy” rating and a $52.00 target price on the stock. Evercore initiated coverage on Avalyn Pharma in a research note on Tuesday. They issued an “outperform” rating and a $51.00 target price on the stock. Wall Street Zen raised Avalyn Pharma to a “hold” rating in a research note on Saturday, May 9th. Finally, Morgan Stanley initiated coverage on Avalyn Pharma in a research note on Tuesday. They issued an “overweight” rating and a $53.00 target price on the stock. Two investment analysts have rated the stock with a Strong Buy rating and two have assigned a Buy rating to the company’s stock. According to data from MarketBeat, the stock has a consensus rating of “Strong Buy” and an average target price of $59.00.
Avalyn Pharma Stock Down 7.4%
Insider Transactions at Avalyn Pharma
In related news, Director Jill Carroll acquired 277,778 shares of Avalyn Pharma stock in a transaction dated Friday, May 1st. The shares were purchased at an average cost of $18.00 per share, with a total value of $5,000,004.00. Following the completion of the purchase, the director owned 2,186,562 shares of the company’s stock, valued at $39,358,116. This represents a 14.55% increase in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink. Also, major shareholder Sr One Capital Management, Llc acquired 555,555 shares of Avalyn Pharma stock in a transaction dated Friday, May 1st. The shares were bought at an average cost of $18.00 per share, for a total transaction of $9,999,990.00. Following the completion of the purchase, the insider directly owned 2,186,562 shares of the company’s stock, valued at approximately $39,358,116. The trade was a 34.06% increase in their position. Additional details regarding this purchase are available in the official SEC disclosure.
Avalyn Pharma Company Profile
We are a clinical-stage biopharmaceutical company pioneering inhaled therapies to transform the treatment paradigm of serious, rare respiratory diseases with significant unmet needs. Our approach is designed to address the limitations of current oral therapies by delivering optimized inhaled formulations of approved oral medicines directly to the lungs to enhance efficacy and minimize systemic exposure that contributes to side effects and treatment discontinuation. Our current pipeline is focused on treating pulmonary fibrosis, a life-threatening disease with a median survival of three to five years, which is a significantly shorter prognosis than that observed for many forms of cancer.
See Also
- Five stocks we like better than Avalyn Pharma
- AI Can’t Reach the Real World Without These 3 Stocks
- Banks Are Buying Back Stock Hand Over Fist, Including These 3 Names
- 2 Aluminum Stocks Poised for Big Tariff-Related Gains
- AutoZone’s Pullback Sets Up a Long-Term Buying Opportunity
Receive News & Ratings for Avalyn Pharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Avalyn Pharma and related companies with MarketBeat.com's FREE daily email newsletter.
